Daniel Joseph Mccarthy Sells 23,693 Shares of Evolent Health, Inc. (NYSE:EVH) Stock

Evolent Health, Inc. (NYSE:EVH) President Daniel Joseph Mccarthy sold 23,693 shares of the firm’s stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $30.89, for a total value of $731,876.77. Following the completion of the transaction, the president now owns 198,809 shares in the company, valued at $6,141,210.01. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Evolent Health Stock Up 0.4 %

EVH opened at $31.74 on Wednesday. The stock has a market cap of $3.69 billion, a price-to-earnings ratio of -25.39 and a beta of 1.54. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.02 and a current ratio of 1.02. The firm’s fifty day moving average is $22.88 and its 200 day moving average is $26.56. Evolent Health, Inc. has a fifty-two week low of $17.98 and a fifty-two week high of $35.00.

Evolent Health (NYSE:EVH) last posted its quarterly earnings results on Thursday, August 8th. The technology company reported $0.30 EPS for the quarter, beating analysts’ consensus estimates of $0.21 by $0.09. The business had revenue of $647.10 million for the quarter, compared to analysts’ expectations of $636.46 million. Evolent Health had a positive return on equity of 6.90% and a negative net margin of 5.07%. The business’s quarterly revenue was up 37.9% on a year-over-year basis. During the same period last year, the firm earned $0.06 earnings per share. On average, sell-side analysts forecast that Evolent Health, Inc. will post 0.9 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in EVH. NBC Securities Inc. grew its holdings in Evolent Health by 16.6% during the 1st quarter. NBC Securities Inc. now owns 2,461 shares of the technology company’s stock valued at $81,000 after buying an additional 350 shares in the last quarter. Principal Financial Group Inc. boosted its position in shares of Evolent Health by 3.2% during the second quarter. Principal Financial Group Inc. now owns 15,594 shares of the technology company’s stock worth $298,000 after acquiring an additional 480 shares during the last quarter. HMS Capital Management LLC grew its stake in Evolent Health by 7.8% during the first quarter. HMS Capital Management LLC now owns 7,419 shares of the technology company’s stock valued at $243,000 after acquiring an additional 538 shares in the last quarter. Ascent Group LLC increased its holdings in Evolent Health by 2.8% in the 1st quarter. Ascent Group LLC now owns 20,330 shares of the technology company’s stock valued at $667,000 after acquiring an additional 550 shares during the last quarter. Finally, SeaCrest Wealth Management LLC lifted its stake in Evolent Health by 6.3% in the 2nd quarter. SeaCrest Wealth Management LLC now owns 10,200 shares of the technology company’s stock worth $195,000 after purchasing an additional 600 shares in the last quarter.

Analyst Ratings Changes

EVH has been the topic of several research reports. Truist Financial reissued a “buy” rating and issued a $33.00 target price on shares of Evolent Health in a research report on Tuesday. JPMorgan Chase & Co. raised their price objective on shares of Evolent Health from $36.00 to $45.00 and gave the stock an “overweight” rating in a report on Monday, August 19th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $42.00 target price on shares of Evolent Health in a report on Monday. Stephens reiterated an “overweight” rating and set a $42.00 price target on shares of Evolent Health in a research note on Tuesday, July 30th. Finally, JMP Securities reduced their price objective on Evolent Health from $34.00 to $31.00 and set a “market outperform” rating for the company in a research note on Friday, August 9th. One investment analyst has rated the stock with a sell rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $40.40.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.